Skip to Content

Pargluva

Treatment for Diabetes Type 2

Bristol-Myers Squibb Provides Regulatory Update for Muraglitazar

PRINCETON, N.J., December 23, 2004 -- Bristol-Myers Squibb Company today announced that the company submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for muraglitazar, an investigational agent under development for the treatment of patients with type 2 diabetes. Bristol-Myers Squibb and Merck & Co., Inc. are collaborators in the global development and commercialization of muraglitazar.

Muraglitazar, discovered by Bristol-Myers Squibb, has the potential to be the first in a novel class of drugs known as dual peroxisome proliferator activated receptor (PPAR) agonists to be approved for marketing in the U.S.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

For further information, please visit www.bms.com

Posted: December 2004

Related Articles

Pargluva (muraglitazar) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.